Wire · regulatory
FDA effort aims to speed up drug development
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA is launching a pilot program to accelerate early-stage drug development by partnering drug companies with qualified research institutions and conducting rolling reviews of applications to reduce delays. This initiative aims to help the U.S. maintain competitiveness against China in biotech clinical trials.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face faster US FDA reviews if you align early with accredited research partners now piloting rolling new drug applications. This could open a new roadmap to speed to clinic compared to traditional pathways dominated by full submissions.
◆ Coverage
1 source · 16 Sep 2026
◆ Related on Wire
◆ Topics